Adenosquamous carcinoma
MONDO:0006074A carcinoma composed of malignant glandular cells and malignant squamous cells.
Also known as: adenosquamous carcinoma, adenosquamous carcinoma (morphologic abnormality), carcinoma, adenosquamous, malignant, mixed adenocarcinoma and epidermoid carcinoma, mixed adenocarcinoma and epidermoid cell carcinoma, mixed adenocarcinoma and squamous carcinoma, mixed adenocarcinoma and squamous cell carcinoma
2783 clinical trials for this condition and its sub-types, 8 tagged with Adenosquamous carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Adenosquamous carcinoma
-
Cervical adenosquamous carcinoma 16 trials
1 sub-type
-
Pancreatic adenosquamous carcinoma 13 trials
-
Adenosquamous lung carcinoma 5 trials
-
Esophageal adenosquamous carcinoma 3 trials
-
Endometrial adenosquamous carcinoma 2 trials
-
Adenosquamous breast carcinoma 0 trials
-
Adenosquamous prostate carcinoma 0 trials
-
Colorectal adenosquamous carcinoma 0 trials
2 sub-types
- Adenosquamous colon carcinoma 0 trials
- Rectal adenosquamous carcinoma 0 trials
-
Gallbladder adenosquamous carcinoma 0 trials
-
Gastric adenosquamous carcinoma 0 trials
-
Liver adenosquamous carcinoma 0 trials
1 sub-type
-
Skin adenosquamous carcinoma 0 trials
-
Thymic adenosquamous carcinoma 0 trials
Most studied deeper sub-types
-
Freezing tumors to boost cancer treatment: early trial underway
Disease control OngoingThis early-phase trial tests a freezing treatment called cryotherapy, given before and during standard chemoradiation, for people with locally advanced esophageal cancer. The main goal is to find the safest number of cryotherapy sessions. Researchers will also check if the freezi…
Phase 1 • Sponsor: Hunter Holmes Mcguire Veteran Affairs Medical Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New pill shows promise against tough cancers in early trial
Disease control OngoingThis Phase 2 trial tests an oral drug called ESK981 in people with advanced pancreatic cancer, neuroendocrine tumors, or neuroendocrine prostate cancer. The goal is to see if the drug can keep the cancer from growing for at least 4 months. Participants take the drug for 5 days, t…
Phase 2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug combo aims to shrink pancreatic tumors before surgery
Disease control OngoingThis early-phase trial tests whether adding a targeted drug called ivosidenib to standard chemotherapy can help shrink pancreatic tumors before surgery. About 16 people with resectable pancreatic cancer that has a specific gene mutation (IDH1) will receive the drug combination fo…
Phase 1 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 26, 2026 13:51 UTC